

Fevzi F Yalniz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8889901/publications.pdf>

Version: 2024-02-01

18
papers

443
citations

840585

11
h-index

887953

17
g-index

19
all docs

19
docs citations

19
times ranked

803
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. <i>EBioMedicine</i> , 2018, 31, 174-181. | 2.7 | 72 |
| 2 | CRP and ferritin in addition to the EASIX score predict CAR-Tâ€“related toxicity. <i>Blood Advances</i> , 2021, 5, 2799-2806. | 2.5 | 57 |
| 3 | Therapy relatedâ€“chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from <i>de novo</i> CMML. <i>American Journal of Hematology</i> , 2018, 93, 65-73. | 2.0 | 49 |
| 4 | Steroid Refractory Chronic Graft-Versus-Host Disease: Cost-Effectiveness Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1920-1927. | 2.0 | 40 |
| 5 | Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3â€“internal tandem duplication mutationâ€“positive acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 3755-3766. | 2.0 | 38 |
| 6 | Prognostic significance of baseline <i>FLT3</i>â€“ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. <i>American Journal of Hematology</i> , 2019, 94, 984-991. | 2.0 | 32 |
| 7 | Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1478-1484. | 2.0 | 31 |
| 8 | Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases. <i>Leukemia</i> , 2018, 32, 2512-2518. | 3.3 | 26 |
| 9 | Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies. <i>Drugs</i> , 2019, 79, 1287-1304. | 4.9 | 22 |
| 10 | Significance of minimal residual disease monitoring by realâ€“time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes. <i>Cancer</i> , 2020, 126, 2183-2192. | 2.0 | 17 |
| 11 | Chronic Cigarette Smoking Affects Left and Right Ventricular Longâ€“Axis Function in Healthy Young Subjects: A Doppler Myocardial Imaging Study. <i>Echocardiography</i> , 2009, 26, 1019-1025. | 0.3 | 15 |
| 12 | Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 689-695. | 0.6 | 14 |
| 13 | A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy. <i>British Journal of Haematology</i> , 2020, 188, 404-412. | 1.2 | 9 |
| 14 | Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors?. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1759-1769. | 2.0 | 9 |
| 15 | Severe odynophagia in a patient developing after azithromycin intake: a case report. <i>Cases Journal</i> , 2010, 3, 48. | 0.4 | 8 |
| 16 | Feasibility of Allogeneic Hematopoietic Stem Cell Transplant for High Risk FLT3-ITD Mutant Patients with Acute Myeloid Leukemia in CR1- a Real Word Analysis. <i>Blood</i> , 2016, 128, 4694-4694. | 0.6 | 1 |
| 17 | The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2020, 136, 17-18. | 0.6 | 1 |
| 18 | Clinical Outcomes Related to the Use of Monoclonal Antibody Therapy for Steroid Refractory Acute Graft-Versus Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2016, 128, 4593-4593. | 0.6 | 0 |